AI Verdict
Both stocks have similar AI ratings. Review detailed metrics below.
KNSA vs KMPB Fundamental Comparison
| Metric | KNSA | KMPB |
|---|---|---|
| Revenue | $677.6M | $4.8B |
| Net Income | $59.0M | $143.3M |
| Net Margin | 8.7% | 3.0% |
| ROE | 10.4% | 5.3% |
| ROA | 7.7% | 1.1% |
| Current Ratio | 3.79x | N/A |
| Debt/Equity | 0.00x | 0.35x |
| EPS | $0.75 | $2.29 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KNSA vs KMPB: Frequently Asked Questions
Is KNSA or KMPB a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), both stocks have similar ratings. KNSA is rated HOLD (68% confidence) while KMPB is rated HOLD (68% confidence). This is not investment advice.
How does KNSA compare to KMPB fundamentally?
Kiniksa Pharmaceuticals International, plc has ROE of 10.4% vs KEMPER Corp's 5.3%. Net margins are 8.7% vs 3.0% respectively.
Which stock pays higher dividends, KNSA or KMPB?
KNSA has a dividend yield of N/A or no dividend while KMPB has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KNSA or KMPB for long term?
For long-term investing, consider that KNSA has HOLD rating with 68% confidence, while KMPB has HOLD rating with 68% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KNSA vs KMPB?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KNSA vs KMPB, both AIs rate them similarly based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.